Rituximab biosimilars

Expert Opinion on Biological Therapy

Volumn 13, Issue 7, 2013, Pages 1049-1062

  Vital, Edward M ^a   Kay, Jonathan ^b   Emery, Paul ^c  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

B cells; Biosimilar; Non Hodgkins lymphoma; Rheumatoid arthritis; Rituximab

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; BIOSIMILAR AGENT; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; PREDNISOLONE; RITUXIMAB; VINCRISTINE SULFATE;

ANCA ASSOCIATED VASCULITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIVIRAL THERAPY; APOPTOSIS; B LYMPHOCYTE; BIOEQUIVALENCE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG APPROVAL; DRUG CONTROL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EUROPEAN UNION; FOLLICULAR LYMPHOMA; HEPATITIS B; HUMAN; IMMUNOGLOBULIN DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; LICENSING; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UNITED STATES;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; HUMANS; NEOPLASMS;

EID: 84878953627     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.787064     Document Type: Review

References (158)

1. United States. Department of Health & Human Services (U.S.) FDA. Public Health Service Act Sec. 262. Regulation of biological products. 2009. Available from: http://www.fda.gov/RegulatoryInformation/Legislation/ucm149278. htm [Cited 17 April 2010]
2. Roche. Full Year Report Highlights 2011. 2011. Available from: http://www.roche.com/home-fyrhighlights.htm#/10 [Cited 21 December 2012]
3. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology-"O brave new world". Nat Rev Rheumatol 2012;8(7):430-6
4. Woodcock J, Griffin J, Behrman R, et al. The FDA's assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov 2007;6(6):437-42
5. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435-45
6. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95(12):3900-8
7. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103(7):2738-43
8. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91(5):1644-52
9. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33
10. Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22(23):4711-16
11. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105(4):1417-23
12. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377(9759):42-51
13. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27(10):1607-14
14. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011;103(23):1799-806
15. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42
16. Zinzani PL, Ascani S, Piccaluga PP, et al. Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol 2000;18(22):3875-7
17. Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood 2012;119(9):1988-91
18. Montserrat E. Rituximab in chronic lymphocytic leukemia. Semin Oncol 2003;30(1 Suppl 2):34-9
19. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112(4):975-80
20. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74
21. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40(2):205-11
22. Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999;97(2):188-96
23. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54(9):2793-806
24. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25):2572-81
25. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54(5):1390-400
26. Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007;66(9):1259-62
27. Turner-Stokes T, Lu TY, Ehrenstein MR, et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) 2011;50(8):1401-8
28. Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011;63(10):3038-47
29. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62(1):222-33
30. Conti F, Perricone C, Ceccarelli F, Valesini G. Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun Rev 2010;9(11):716-20
31. Ramos-Casals M, Diaz-Lagares C, Khamashta MA. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum 2009;61(9):1281-2
32. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363(3):221-32
33. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363(3):211-20
34. Leveille C, Chandad F, Al-Daccak R, Mourad W. CD40 associates with the MHC class II molecules on human B cells. Eur J Immunol 1999;29(10556806):3516-26
35. Petrie RJ, Deans JP. Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J Immunol 2002;169(12218101):2886-91
36. Szollosi J, Horejsi V, Bene L, et al. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol 1996;157(8816400):2939-46
37. Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003;278(12920111):42427-34
38. Bubien JK, Zhou LJ, Bell PD, et al. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993;121(7684739):1121-32
39. Uchida J, Lee Y, Hasegawa M, et al. Mouse CD20 expression and function. Int Immunol 2004;16(14688067):119-29
40. Smeland EB, Beiske K, Ek B, et al. Regulation of c-myc transcription and protein expression during activation of normal human B cells. Exp Cell Res 1987;172(3308492):101-9
41. Holder M, Grafton G, MacDonald I, et al. Engagement of CD20 suppresses apoptosis in germinal center B cells. Eur J Immunol 1995;25(7489758):3160-4
42. Clark EA, Shu G. Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors. J Immunol 1987;138(3):720-5
43. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51(11845256):15-24
44. Pedersen IM, Buhl AM, Klausen P, et al. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002;99(11830481):1314-19
45. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000;48(10752475):673-83
46. Tedder TF, Forsgren A, Boyd AW, et al. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol 1986;16(3091375):881-7
47. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6(4):443-6
48. Hatjiharissi E, Hansen M, Santos DD, et al. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 2007;7(4):286-90
49. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99(3):754-8
50. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21(21):3940-7
51. Persky DO, Dornan D, Goldman B, et al. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 2012;97(6):937-42
52. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48(2):455-9
53. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101(12393572):949-54
54. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171(3):1581-7
55. van der Kolk LE, Grillo-Lopez AJ, Baars JW, et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115(4):807-11
56. Vervoordeldonk SF, Merle PA, van Leeuwen EF, et al. Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. Cancer 1994;73(8306242):1006-11
57. Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008;5(3):e64
58. Arts EE, Jansen TL, Den Broeder A, et al. Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2011;70(5):877-8
59. Das S, Fernandez Matilla M, Dass S, et al. Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis. Ann Rheum Dis 2012; in press
60. Cragg MS, Morgan SM, Chan HTC, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101(12393541):1045-52
61. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8(15564720):140- 74
62. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005;174(15634903):817- 26
63. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19(11304767):2153-64
64. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(20888994):1164-74
65. Manshouri T, Do K-a, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101(12446458):2507-13
66. Robak T, Jamroziak K, Gora-Tybor J, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010;28(20212251):1863-9
67. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27(19075274):498- 503
68. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21(12721250):1746-51
69. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(9704735):2825-33
70. Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007;62(1):43-52
71. Cragg MS, Bayne MB, Tutt AL, et al. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 2004;104(15213098):2540-2
72. Beum PV, Kennedy AD, Taylor RP. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J Immunol Methods 2004;289(15251416):97-9109
73. Hong K, Presta LG, Lu Y, et al. Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. J Immunol Methods 2004;294(15604027):189-97
74. Alatrash G, Albitar M, O'Brien S, et al. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 2010;148(3):386-93
75. Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006;177(10):7435-43
76. Beum PV, Kennedy AD, Williams ME, et al. The shaving reaction: rituximab/ CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006;176(4):2600-9
77. Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002;13(12123339):928-43
78. Scheidhauer K, Wolf I, Baumgartl H-J, et al. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002;29(12271407):1276-82
79. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101(12393404): 466-8
80. Hiroshima Y, Tajima K, Shiono Y, et al. Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites. Ann Hematol 2012;91(9):1499-500
81. Kim H, Csaky KG, Chan CC, et al. The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res 2006;82(5):760-6
82. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDECC2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84(7522629):2457-66
83. Ogura M, Morishima Y, Kagami Y, et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci 2006;97(16630123):305-12
84. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005;45(7):792-801
85. Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47(9):1119-28
86. Vital EM, Dass S, Rawstron AC, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010;62(5):1273-9
87. Vital EM, Dass S, Rawstron AC, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010;62(5):1273-9
88. Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008;67(7):917-25
89. Vos K, Thurlings RM, Wijbrandts CA, et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56(3):772-8
90. Teng YK, Levarht EW, Toes RE, et al. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 2009;68(6):1011-16
91. Owczarczyk K, Lal P, Abbas AR, et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med 2011;3(101):101ra92
92. Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 2011;63(3):603-8
93. Vital EM, Dass S, Buch MH, et al. A randomised, double-blind placebo controlled trial on the effects of increased dose rituximab in patients with initial incomplete depletion - the extended treatment with rituximab in rheumatoid arthritis (EXTRRA) Trial. Ann Rheum Dis 2010;69(Suppl3):147
94. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 2010;49(9):1683-93
95. Hillmen P. Chronic lymphocytic leukaemia-moving towards cure? Lancet 2010;376(9747):1122-4
96. Stilgenbauer S BR, Schnaiter A, Paschka P, Rossi M. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. American Society of Hematology, Georgia, USA; 2012
97. Maeda T, Yamada Y, Tawara M, et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDECC2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int J Hematol 2001;74(11530808):70-5
98. Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69(2):409-12
99. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54(16649186):1390- 400
100. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoImmunity and rituximab registry. Arthritis Rheum 2010;62(9):2625-32
101. Dunleavy K, Tay K, Wilson WH. Rituximab-associated neutropenia. Semin Hematol 2010;47(2):180-6
102. Wang YH, Fan L, Wang L, et al. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy. Supportive Care Cancer 2012;;21(5):1265-71
103. Chen XQ, Peng JW, Lin GN, et al. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol 2012;29(2):1237-41
104. Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004;83(1):58-60
105. Hamaki T, Kami M, Kusumi E, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001;68(4):292-4
106. Herold T, Seiler T, Egensperger R, et al. Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 2012;53(1):169-72
107. Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009;60(11):3225-8
108. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113(20):4834-40
109. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002;99(4):1486-8
110. Biophoenix. Biosimilars, Biogenerics and follow-on biologics. 2007. Available from: http://www.scripintelligence.com/multimedia/archive/00000/ BS1342-117a.pdf [Cited 18 November 2011]
111. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v4-8
112. Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011;29(4):310-12
113. Fox A. Biosimilar medicines-new challenges for a new class of medicine. J Biopharm Stat 2010;20(1):3-9
114. Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011;29(4):310-12
115. ICH. Quality of Biotechnological Products Q5A - Q5E
116. Agency EM. Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues. 2012. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/ 06/WC500128686.pdf [cited 15th February 2013]
117. da Silva A KU, Meyer I, Papandrikopoulou A, et al. Target-directed development of a proposed biosimilar rituximab (GP2013): comparability of antibody-dependent cellular cytotoxicity activity and pre-clinical pharmacokinetics and pharmacodynamics with originator rituximab. American College of Rheumatology, Washington DC, USA; 2012
118. Online GaBI. US$54 billion worth of biosimilar patents expiring before 2020. 2011. Available from: http://www.gabionline.net/Biosimilars/ Research/US-54-billion-worth-of-biosimilar-patentsexpiring-before-2020 [Cited 12 September 2012]
119. Publications-Office-of-the-European-Union. Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products 18 June 1992. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31992R1768:EN:HTML [Cited 12 September 2012]
120. Committee-for-Medicinal-Products-for-Human-Use. Guideline on similar biological medicinal products. 2005. Available from: http://www.emea.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003517.pdf [cited 12 September 2012]
121. Committee-for-Medicinal-Products-for- Human-Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2006. Available from: http://www.emea.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003920.pdf [Cited 12 September 2012]
122. Knezevic I, Griffiths E. Biosimilars-global issues, national solutions. Biologicals 2011;39(21924623):252-5
123. Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol 2010;28(20062035):28-31
124. Committee-for-Medicinal-Products-for-Human-Use. Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2011. Available from: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2011/10/WC500115611.pdf [Cited 12 September 2012]
125. Administration UFaD. FDA HR 3590-686. Patient protection and affordable care act. Title VII-Improving access to innovative medical therapies. Subtitle A -Biologics price competition and innovation. Sec. 7002. Approval pathway for biosimilar biological products. 2010. Available from: http://www.gpo.gov/fdsys/ pkg/BILLS-111hr3590eas/pdf/BILLS-111hr3590eas.pdf [cited 12 September 2012]
126. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Eng J Med 2011;365(21812668):385-8
127. Administration UFaD. Guidance for industry. Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. Department of Health & Human Services. 2012. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf [Cited 12 September 2012]
128. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006;21(Suppl 5):v9-12
129. Viswabandya A, Prashanthi PV, Raju CN, et al. Pharmacokinetic and pharmacodynamic evaluation of a biosimilar rituximab in newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP (Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone). Blood (ASH Annual Meeting Abstracts 2007 November 16) 2007;110(11):4491
130. Initiative GaB. Mexican biocomparables guidelines come into force Posted 18/05/ 2012. 2012. Available from: http://www.gabionline.net/layout/set/print/ content/view/full/1906 [Cited 28 December 2012]
131. Curaxys. Rituximab. 2012. Available from: http://curaxys.com/products/ rituximab/ [cited 12 September 2012]
132. Newswire P. iBio Announces Production of Biosimilar Rituximab with its iBioLaunch Technology. 2012. Available from: http://www.prnewswire.com/news- releases/ibioannounces-production-of-biosimilarrituximab-with-its-ibiolaunch- technology-131132383.html [Cited 12 September 2012]
133. Li H, Sethuraman N, Stadheim TA, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotech 2006;24(2):210-15
134. Gasdaska JR, Sherwood S, Regan JT, Dickey LF. An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab. Mol Immunol 2012;50(3):134-41
135. Ostergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010;62(8):2227-38
136. Hoyle M, Crathorne L, Garside R, Hyde C. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Health Technol Assess 2011;15(Suppl 1):61-7
137. Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010;21(9):1870-6
138. Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58(9):2652-61
139. Harigai M, Tanaka Y, Maisawa S. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study. J Rheumatol 2012;39(3):486-95
140. Rigby W, Tony HP, Oelke K, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012;64(2):350-9
141. Stohl W, Gomez-Reino J, Olech E, et al. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis 2012;71(8):1289-96
142. Tak PP, Mease PJ, Genovese MC, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012;64(2):360-70
143. NIH. A study to evaluate ocrelizumab in patients with nephritis due to systemic lupus erythematosus (BELONG). 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00626197 [Cited 28 December 2012]
144. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378(9805):1779-87
145. Chaudhuri A. Ocrelizumab in multiple sclerosis: risks and benefits. Lancet 2012;379(9822):1196-7; author reply 97
146. NIH. A study of MabThera (Rituximab) subcutaneous vs. MabThera (Rituximab) intravenous in patients with follicular non-Hodgkin's lymphoma. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01200758?term= mabthera&rank=2 [cited 10 September 2012]
147. NIH. A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808- 002 AM2 EXT 1). 2012
148. NIH. Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808- 001 AM2). 2011
149. NIH. Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial (Triad-DLBCL). 2012
150. NIH. Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis (Triad RA). 2012
151. NIH. GP2013 in the treatment of RA patients refractory to or intolerant of standard therapy. 2012. Available from: http://clinicaltrials.gov/ct2/show/ NCT01274182 [Cited 31 October 2012]
152. NIH. A Pharmacokinetic/ Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-0]. 2012
153. EUDRACT. A randomized, double-blind, parallel group, multicenter trial to compare the efficacy, safety, pharmacodynamics and pharmacokinetics of SAIT101 to MabThera in subjects with severe rheumatoid arthritis. 2012. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=SAIT101
154. EUDRACT. A multicenter, double-blind, randomized, active controlled, parallel-group study to evaluate the efficacy, safety, tolerability and pharmacodynamic profiles of TL011 infusions compared with MabThera-(rituximab) in subjects with severe, active rheumatoid arthritis treated with methotrexate (MTX). 2012
155. NIH. Efficacy, pharmacokinetics, and safety of BI 695500 in patients with rheumatoid arthritis. 2012. Available from: http://clinicaltrials.gov/ct2/show/ NCT01682512?term=BI695500&rank=1 [Cited 28 December 2012]
156. Initiative GaB. Samsung halts biosimilar rituximab development. 2012. Available from: http://www.gabionline.net/Biosimilars/News/Samsung-halts- biosimilar-rituximabdevelopment [Cited 03 January 2013]
157. Initiative GaB. Teva halts phase III biosimilar trial. 2012. Available from: http://www.gabionline.net/Biosimilars/News/Tevahalts-phase-III-biosimilar- rituximab-trial [Cited 03 January 2013]
158. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med 2011;365(5):385-8